Fluorine-containing long-chain compound as well as self-assembly structure, preparation method and application thereof

By designing covalently modified links of fluoroprofen and 4-octyl itaconic acid, self-assembly and sustained release of fluoroprofen prodrugs in the prior art is solved. The problem of this enhances the anti-inflammatory and analgesic effects and reduces adverse reactions.

CN119039147AActive Publication Date: 2024-11-29WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410673643.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-29
Filing Date
2024-05-28
Publication Date
2024-11-29
Estimated Expiration
2044-05-28

AI Technical Summary

Technical Problem

The existing flubiprofen prodrugs quickly transform into active form at the injection site, limiting their prolonged release potential, and lacking covalent modification links that can successfully release active drugs in macrophage environments, affecting their anti-inflammatory and analgesic effects. .

Method used

A class of fluorine-containing long chain compounds were designed to connect flubiprofen and 4-octyl itaconic acid by covalent modification, and to construct self-assembled compounds to achieve the easing of flubiprofen and 4-octyl itaconic acid. Release the effect, enhance the anti-inflammatory and analgesic effects and reduce adverse reactions.

Benefits of technology

The sustained release effects of flubiprofen and 4-octyl itaconic acid were achieved, which enhanced the anti-inflammatory and analgesic effects, reduced adverse reactions, and improved the delivery efficiency and stability of the drug through self-assembly structures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039147A_ABST
    Figure CN119039147A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a fluorine-containing long-chain compound as well as a self-assembly structure, a preparation method and application thereof. The structural formula of the fluorine-containing long-chain compound disclosed by the invention is shown as a formula I, the flurbiprofen and 4-octylitaconic acid sustained-release preparation can generate self-assembly, and realizes the sustained-release effect of flurbiprofen and 4-octylitaconic acid (or analogues of flurbiprofen and 4-octylitaconic acid), thereby achieving the effects of enhancing anti-inflammatory and analgesic curative effects and reducing adverse reactions of flurbiprofen and 4-octylitaconic acid, # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a fluorine-containing long-chain compound, a self-assembly structure thereof, a preparation method thereof and a use thereof. Background Art

[0002] Pain is an important public health issue. According to the International Society for Pain, one in five people in the world experience chronic pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used antipyretic, anti-inflammatory and analgesic drugs in clinical practice (Barkin 2015), and are widely used to treat and relieve various mild and moderate pain. Approximately 30 billion doses of NSAIDs are consumed in the United States each year (Macedo et al. 2021).

[0003] Flurbiprofen is a derivative of phenylalkanoic acid and is the most potent propionic acid nonsteroidal anti-inflammatory drug known to date for analgesia. It reduces inflammation and pain by inhibiting cyclooxygenase and reducing the production of prostaglandins. Studies have shown that flurbiprofen can also exert anti-inflammatory effects by inhibiting the expression of inducible nitric oxide synthase in RAW264.7 macrophages (Hinz et al. 2001). However, due to the presence of its free carboxylic acid group (-COOH), flurbiprofen may cause adverse gastrointestinal reactions. Therefore, it is often designed as a prodrug to mask this group. At present, many ester prodrugs have been synthesized, and some researchers have tried to use the "mutual prodrug" method to combine two pharmacologically active substances to provide synergistic effects and reduce the adverse reactions of flurbiprofen (Ashraf et al. 2016).

[0004] Despite the growth in research on flurbiprofen prodrugs, there are still some inherent problems. For example, once released from the injection site, the prodrug is usually rapidly converted to its active form, limiting the potential for extended release of the prodrug. To address these issues, "self-assembled prodrugs" can achieve maximum drug loading efficiency and controlled extended release kinetics. The design method of self-assembled prodrugs is usually to covalently modify the known prodrug with additional biocompatible parts (such as natural fatty acids) to convert the prodrug into a self-deliverable carrier. This method can increase the delivery amount of the parent drug and may experience slower degradation (Cheetham et al. 2017). Although there have been many reports on self-assembled prodrugs of non-steroidal anti-inflammatory drugs, most of the covalently modified additional biocompatible parts are molecules with no pharmacological activity, so the development of a self-assembled nano drug delivery system combining two pharmacologically active substances has significant innovation and application value.

[0005] 4-Octylitaconate is a derivative of the small molecule metabolite itaconate, which can be hydrolyzed into itaconate in macrophages. Itaconate is an important regulator of immunity and inflammation. In macrophages, itaconate and its derivatives have been shown to inhibit the tricarboxylic acid cycle enzyme succinate dehydrogenase and prevent the production of reactive oxygen species in complex I (Shi et al. 2022). In addition, studies have shown that 4-octylitaconate can exert an anti-inflammatory effect by targeting glyceraldehyde phosphate dehydrogenase, blocking glycolytic metabolism, and reducing the release of inflammatory factors (Liao et al. 2019). However, its significant cell permeability means that 4-octylitaconate may enter normal cells and interfere with metabolism.

[0006] Flurbiprofen and 4-octylitaconic acid both exert anti-inflammatory effects by acting on macrophages, so designing the two together as self-assembling prodrugs can enhance anti-inflammatory and analgesic effects and reduce adverse reactions, which is a very promising idea for drug development. However, there is currently a lack of relevant research on the covalent modification connection of flurbiprofen and 4-octylitaconic acid. How to design the connected molecular chain to construct a prodrug that can achieve self-assembly and can smoothly release active drugs in the macrophage environment is still a problem that needs to be solved in this field. Summary of the invention

[0007] In view of the problems existing in the prior art, the present invention provides a class of fluorine-containing long-chain compounds having anti-inflammatory and analgesic effects, and further provides a preparation method, a self-assembly structure and uses of the compound.

[0008] The compound shown in formula I, or its salt, or its crystal form, or its stereoisomer, the structural formula of the compound shown in formula I is as follows:

[0009]

[0010] in,

[0011] X 1 is selected from oxygen, carbonyl, substituted or unsubstituted methylene; wherein the substituent is selected from methyl;

[0012] X 2 is selected from oxygen or carbonyl;

[0013] X 3 is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH 2 ;

[0014] X 4 is selected from substituted or unsubstituted methylene; wherein the substituent is selected from methyl or =CH 2 ;

[0015] X 5is selected from oxygen, carbonyl, substituted or unsubstituted methylene; wherein the substituent is selected from =CH 2 ;

[0016] X 6 is selected from oxygen or carbonyl;

[0017] X 7 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from methyl or =CH 2 ;

[0018] X 8 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH 2 ;

[0019] X 9 is absent, or is selected from carbonyl;

[0020] X 10 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH 2 ;

[0021] X 11 is absent, or is selected from substituted or unsubstituted methylene; wherein the substituent is selected from =CH 2 ;

[0022] X 12 is absent, or is selected from carbonyl;

[0023] X 13 is absent, or is selected from oxygen;

[0024] R is selected from H or C 1 ~C 12 alkyl.

[0025] Preferably, the compound has a structural formula as shown in Formula II:

[0026]

[0027] in,

[0028] R 1 is selected from methyl or H,

[0029] R 2 Connected to other parts of the molecule through single or double bonds; when R 2 When connected to the rest of the molecule by a single bond, R 2 Select from H; when R 10 When connected to the rest of the molecule through a double bond, R 2 Selected from =CH 2 ;

[0030] R 3 Connected to other parts of the molecule through single or double bonds; when R 3 When connected to the rest of the molecule by a single bond, R 3 Select from H; when R 11 When connected to the rest of the molecule through a double bond, R 3 Selected from =CH 2 ;

[0031] R is selected from H or C 1 ~C 12 alkyl.

[0032] Preferably, the compound has the following structural formula:

[0033]

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040]

[0041] Preferably, the compound has a structural formula as shown in Formula III:

[0042]

[0043] in,

[0044] R 4 is selected from H or methyl,

[0045] R 5 Connected to other parts of the molecule through single or double bonds; when R 5 When connected to the rest of the molecule by a single bond, R 5 Select from H; when R 5 When connected to the rest of the molecule through a double bond, R 5 Selected from =CH 2 ;

[0046] R 6 Connected to other parts of the molecule through single or double bonds; when R 6When connected to the rest of the molecule by a single bond, R 6 Select from H; when R 6 When connected to the rest of the molecule through a double bond, R 6 Selected from =CH 2 ;

[0047] R is selected from C 1 ~C 12 alkyl.

[0048] Preferably, the compound has the following structural formula:

[0049]

[0050] Preferably, the compound has a structural formula as shown in Formula IV:

[0051]

[0052] in,

[0053] R 7 Connected to other parts of the molecule through single or double bonds; when R 7 When connected to the rest of the molecule by a single bond, R 7 Select from H; when R 7 When connected to the rest of the molecule through a double bond, R 7 Selected from =CH 2 ;

[0054] R 8 Connected to other parts of the molecule through single or double bonds; when R 8 When connected to the rest of the molecule by a single bond, R 8 Select from H; when R 8 When connected to the rest of the molecule through a double bond, R 8 Selected from =CH 2 ;

[0055] R is selected from C 1 ~C 12 alkyl.

[0056] Preferably, the compound has the following structural formula:

[0057]

[0058] The present invention also provides a method for preparing the above compound, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, comprising the following steps:

[0059]

[0060] Step 1, reacting flurbiprofen with a chlorination reagent to obtain compound I-53-1;

[0061] Step 2, reacting compound I-53-1, paraldehyde and an iodination reagent to obtain compound I-53-2;

[0062] Step 3, reacting compound I-53-2 and compound F to obtain the compound represented by formula II.

[0063] Preferably, in step 1, the chlorination agent is selected from at least one of oxalyl chloride, thionyl chloride, phosphorus trichloride, phosphorus pentachloride or triphosgene;

[0064] and / or, the reaction is performed with or without a solvent; when a solvent is used in the reaction, the solvent is selected from at least one of dichloromethane, petroleum ether, n-hexane, tetrahydrofuran, toluene or benzene;

[0065] and / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of N,N-dimethylformamide, N,N-dimethylaniline and pyridine, triethylamine or N-methylpyrrolidone;

[0066] And / or, the reaction temperature ranges from -20°C to 80°C.

[0067] Preferably, in step 2, the iodination agent is selected from at least one of sodium iodide or elemental iodine;

[0068] and / or, the reaction solvent is selected from at least one of dichloromethane and acetonitrile;

[0069] And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from AlCl 3 or at least one of zinc chloride;

[0070] And / or, the reaction temperature ranges from 0°C to 40°C.

[0071] Preferably, in step 3, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane or N,N-dimethylformamide;

[0072] And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of DBU, sodium carbonate, potassium carbonate, cesium carbonate or triethylamine;

[0073] And / or, the reaction temperature ranges from 0°C to 40°C.

[0074] The present invention also provides a method for preparing the above compound, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, comprising the following steps:

[0075]

[0076] Step a, reacting flurbiprofen with compound C to obtain compound D;

[0077] Step b, reacting compound D with compound E to obtain a compound represented by formula III.

[0078] Preferably, in step 4, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane or N,N-dimethylformamide;

[0079] And / or, the reaction is carried out under the action of a base, wherein the base is selected from tetrabutylammonium hydrogen sulfate, sodium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate or triethylamine

[0080] And / or, the reaction temperature is in the range of 0°C to 40°C.

[0081] Preferably, in step 5, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, chloroform, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane, N,N-dimethylformamide, N,N-dimethylacetamide or DMSO;

[0082] and / or, the reaction is carried out under the action of a base, wherein the base is selected from at least one of DBU, sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, potassium bicarbonate or sodium bicarbonate;

[0083] And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of sodium iodide and potassium iodide;

[0084] And / or, the reaction temperature ranges from 0°C to 80°C.

[0085] The present invention also provides a self-assembled structure formed by self-assembly of the above compound, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof.

[0086] The present invention also provides use of the above compound, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, or the above self-assembled structure in the preparation of anti-inflammatory and / or analgesic drugs.

[0087] The present invention also provides a drug for anti-inflammatory and / or analgesic purposes, which is prepared by using the above-mentioned compound, or its salt, or its crystal form, or its stereoisomer, or self-assembled structure as an active ingredient and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0088] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for groups or terms in this document apply to the groups or terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art can give them should be given based on the disclosure and context.

[0089] "Substitution" means that the hydrogen atoms in a molecule are replaced by other different atoms or molecules. "Substitution" can mean substitution by one group or by at least two groups.

[0090] The minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix C a -C b Alkyl refers to any alkyl group containing from "a" to "b" carbon atoms. Thus, for example, "C 1 -C 4 "Alkyl" refers to an alkyl group containing 1 to 4 carbon atoms.

[0091] "Alkyl" refers to a saturated hydrocarbon chain having the specified number of member atoms. 1 -C 6 Alkyl refers to an alkyl group having 1 to 6 member atoms, for example 1 to 4 member atoms. The alkyl group can be straight or branched. Representative branched alkyl groups have one, two or three branches. The alkyl group may be optionally substituted with one or more substituents as defined herein. Alkyl includes methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl. The alkyl group may also be part of other groups, such as C 1 -C 6 Alkoxy.

[0092] "Alkylene" refers to a divalent functional group formed by a saturated hydrocarbon chain having a specified number of member atoms, for example: "—CH 2 —” or “—CH 2 —CH 2 —”.

[0093] The hydrogen atoms in the compounds of the present invention may be various isotopes of hydrogen, such as protium (1H), deuterium (2H) or tritium ( 3 H).

[0094] The term "pharmaceutically acceptable" means that a carrier, vehicle, diluent, excipient, and / or formed salt is generally chemically or physically compatible with the other ingredients that constitute a pharmaceutical dosage form and physiologically compatible with the receptor.

[0095] The terms "salt" and "pharmaceutically acceptable salt" refer to acidic and / or basic salts of the above-mentioned compounds or their stereoisomers, formed with inorganic and / or organic acids and bases, and also include zwitterionic salts (inner salts), and also include quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained directly in the final separation and purification of the compound. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base appropriately (e.g., equivalent). These salts may form a precipitate in the solution and be collected by filtering, or be recovered after solvent evaporation, or be obtained by freeze drying after reaction in an aqueous medium. The salt described in the present invention can be a hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate of the compound.

[0096] The present invention connects flurbiprofen and 4-octyl itaconic acid by covalent modification, constructs a class of long-chain compounds, which can self-assemble to achieve the sustained release effect of flurbiprofen and 4-octyl itaconic acid drugs (or their analogs), thereby achieving the effect of enhancing the anti-inflammatory and analgesic efficacy and reducing adverse reactions. Therefore, the present invention has a good application prospect.

[0097] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0098] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] Figure 1 This is an in vitro decomposition test of compound I-53 in rat plasma.

[0100] Figure 2 The analgesic efficacy of the compound of the present invention in the chronic inflammatory pain model. DETAILED DESCRIPTION

[0101] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0102] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6The NMR measurements were performed using a Bruker Avance III 400 nuclear magnetic spectrometer, and the solvent used was deuterated dimethyl sulfoxide (d 6 -DMSO) or deuterated chloroform (CDCl 3 ), and the internal standard was tetramethylsilane (TMS).

[0103] LCMS determination was performed using (Agilent LCMS1260-6110) (ESI), column: Waters X-Bridge C18 (50 mm x 4.6 mm x 3.5 μm). Column temperature: 40°C; flow rate: 2.0 mL / min; mobile phase: 95% [water + 0.05% TFA] and 5% [CH 3 CN+0.05% TFA] to 0% [water+0.05% TFA] and 100% [CH 3 CN+0.05% TFA], maintained under this condition for 1 min, and then gradually increased to 95% [water+0.05% TFA] and 5% [CH 3 CN + 0.05% TFA], and maintain this condition for another 0.7 min.

[0104] 1) Medicinal materials and reagents

[0105] The thin layer chromatography silica gel plate used was HSGF254 silica gel plate produced by Yantai Xinnuo Chemical Co., Ltd., with a thickness of 1 mm.

[0106] Thin layer chromatography (TLC) used products from Yantai Jiangyou Silica Gel Development Co., Ltd., with a specification of 0.2±0.03 mm.

[0107] Column chromatography generally uses 100-200 mesh or 200-300 mesh silica gel produced by Rushan Sun Desiccant Co., Ltd. (Weihai, Shandong) as a carrier.

[0108] 2) Main instruments

[0109] Sartorius BSA124S electronic balance (Sartorius Scientific Instruments Beijing Co., Ltd.);

[0110] 98-2 magnetic stirrer (Shanghai Silu Instrument Co., Ltd.);

[0111] MS-H-PRO + CNC heating magnetic stirrer (Dalong Xingchuang Experimental Instrument Beijing Co., Ltd.);

[0112] ZF-I three-purpose UV instrument (Shanghai Anting Electronic Instrument Factory);

[0113] R-201 rotary evaporator (Shanghai Shenshun Biotechnology Co., Ltd.);

[0114] W201D constant temperature water bath (Shanghai Shenshun Biotechnology Co., Ltd.);

[0115] SHB-III circulating water vacuum pump (Zhengzhou Huicheng Science and Technology Industry and Trade Co., Ltd.);

[0116] DLSB-5 / 20℃ low temperature cooling circulation pump (Gongyi Yuhua Instrument Co., Ltd.);

[0117] 2XZ-2 rotary vane vacuum pump (Linhai Yonghao Vacuum Equipment Co., Ltd.);

[0118] Example 1 Preparation of Compound I-9

[0119]

[0120] Step 1: At room temperature, flurbiprofen 1-1 (1.00 g, 4.1 mmol) was dissolved in dry dichloromethane (50 mL), and the ice-water bath was cooled to 0°C. Oxalyl chloride (1.04 g, 8.2 mmol) and a catalytic amount of dry DMF (0.1 mL) were slowly added to the reaction system in sequence. After the addition, the mixture was naturally warmed to room temperature and stirred for 10 h. The sample was taken and the crude product was spin-dried to obtain a crude spectrum. The raw material was basically converted. The crude product was concentrated under reduced pressure to obtain a crude product FI-1, which was directly used in the next step without purification. 1 H NMR (400 MHz, CDCl 3 )δ7.60-7.50(m,2H),7.41(dt,J=21.8,7.6Hz,4H),7.23-7.05(m,2H),3.79(q,J=7.2Hz,1H),1.57(d,J=7.2Hz,3H).

[0121] Step 2: Dissolve NaI (741 mg, 8.2 mmol) and triacetaldehyde 1-2 (1.83 g, 13.8 mmol) in dry dichloromethane (50 mL) in an ice-water bath at 0°C. 3 (16.5 mg, 0.1 mmol) and I 2 (7.3 mg, 0.3 mmol) were added to the reaction system in sequence and stirred at room temperature for 12 h. Water (50 mL) was added to the reaction system and extracted with dichloromethane (3 × 10 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure, and then purified by column to obtain 1.4 g of product FI-2 with a yield of 86%. 1 H NMR (400 MHz, CDCl 3)δ7.59-7.50(m,2H),7.49-7.30(m,4H),7.26(s,1H),7.20-7.01(m,2H),6.55(dd,J=12 .6,6.0Hz,1H),3.78(q,J=7.3Hz,1H),1.77(dd,J=15.0,5.8Hz,2H),1.64-1.48(m,4H).

[0122]

[0123] Step 3: Place lactic acid 1-14 (3.7 mL, 51 mmol) and acetic acid 1-15 (15 mL) in a 50 mL bottle, slowly add acetyl chloride (11 mL) at 0°C, and move to room temperature for 24 h. Concentrate under reduced pressure to obtain 8 g of crude product 1-16, with 55% acetic acid remaining in the crude spectrum. Use toluene to azeotrope the remaining acetic acid, and 35% acetic acid still remains in the crude spectrum.

[0124] Step 4: Dissolve the acid 1-16 (4.0 g, 30 mmol) and tert-butanol 1-17 (4.9 g, 66 mmol) in dichloromethane (90 mL), add 4-dimethylaminopyridine (1.1 g), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.5 g) in three batches at 0°C, react at room temperature for 3 h, extract with dichloromethane (3×20 mL), combine the organic phases, dry with anhydrous Na2SO4, filter, concentrate under reduced pressure, and purify by column to obtain 930 mg of product 1-18 with a yield of 16%.

[0125] Step 5: Dissolve the precursor compound 1-18 (930 mg, 4.9 mmol) in methanol (2 mL), dissolve potassium carbonate (2 g) in water (7 mL) and methanol (4 mL), add 4-dimethylaminopyridine (1.1 g), add the potassium carbonate solution dropwise to the reaction solution at 0 ° C, react at room temperature for 3 h, extract with dichloromethane (3×10 mL), combine the organic phases and precipitate with anhydrous Na 2 SO 4 After drying, suction filtration and concentration under reduced pressure, 300 mg of crude product 1-19 was obtained with a yield of 42%.

[0126] Step 6: Dissolve 490 mg of carboxylic acid compound 1-10 and 300 mg of alcohol 1-19 in dichloromethane (10 mL), add 4-dimethylaminopyridine (126 mg, 1.0 mmol), N,N-diisopropylethylamine (582 mg, 6.15 mmol), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (589 mg, 3.0 mmol) at 0°C, react at room temperature for 8 h, concentrate the reaction solution by spin drying, and purify by column to obtain 285 mg of product 1-20 with a yield of 48%.

[0127] Step 7: Dissolve 285 mg of the precursor compound 1-20 in dichloromethane (2 mL), add trifluoroacetic acid (0.3 mL), react at room temperature for 8 h, concentrate the reaction solution under reduced pressure, and purify by column to obtain 150 mg of the product 1-21, with a yield of 62%. 1 H NMR (400 MHz, CDCl 3 )δ6.45(s,1H),5.81(s,1H),5.25(q,J=7.1Hz,1H),3.51-3.26(m,2H),1.36-1.14(m,15H),0.88(t,J=6.6Hz,3H).

[0128]

[0129] Step 8: Precursor compound FI-2 (200 mg, 0.5 mmol), carboxylic acid compound 1-21 (150 mg, 0.5 mmol) and DBU (97 μL) were dissolved in dry acetonitrile (5 mL) at room temperature and stirred at room temperature for 12 h. According to TLC monitoring, the remaining amount of the precursor compound was about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system, extracted with ethyl acetate (3×10 mL), and the organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column to obtain 122 mg of light yellow oily product I-9 with a yield of 42%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(d,J=7.7Hz,2H),7.50-7.31(m,4H),7.18-7.05(m,2H),6.97-6.82(m,1H),6.46-6.28(m,1H),5.82-5.68(m,1H),5.20-4.87 (m,1H),4.18-3.99(m,2H),3.75(q,J=7.2Hz,1H),3.49-3.21(m,2H),1.72-1.39(m,11H),1.36-1.22(m,10H),0.87(t,J=6.6Hz,3H).

[0130] Example 2 Preparation of Compound I-22

[0131]

[0132] Step 1: Dissolve 433 mg of carboxylic acid compound 1-9 and 262 mg of alcohol 1-19 in dichloromethane (8 mL), add 4-dimethylaminopyridine (110 mg, 0.9 mmol), N,N-diisopropylethylamine (508 mg, 5.37 mmol), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (514 mg, 2.68 mmol) at 0°C, react at room temperature for 8 h, concentrate the reaction solution by spin drying, and purify by column to obtain 282 mg of product 1-23, with a yield of 49%.

[0133] Step 2: Dissolve 282 mg of the precursor compound 1-25 in dichloromethane (2 mL), add trifluoroacetic acid (0.3 mL), react at room temperature for 8 h, concentrate the reaction solution under reduced pressure, and purify by column to obtain 160 mg of the product 1-26 with a yield of 67%. 1 H NMR (400 MHz, CDCl 3 )δ6.36(s,1H),5.78(s,1H),5.16(q,J=7.1Hz,1H),3.50-3.33(m,2H),1.41-1.20(m,15H),0.87(t,J=6.6Hz,3H).

[0134]

[0135] Step 3: Dissolve the precursor compound FI-2 (200 mg, 0.51 mmol), carboxylic acid compound 1-26 (160 mg, 0.51 mmol) and DBU (97 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system and extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column to obtain 137 mg of light yellow oily product I-22 with a yield of 46%. 1 H NMR (400 MHz, CDCl 3)δ7.53(d,J=7.7Hz,2H),7.49-7.31(m,4H)7.18-7.02(m,2H),6.95-6.82( m,1H),6.42-6.22(m,1H),5.82-5.61(m,1H),5.16-4.89(m,1H),4.13(p,J =6.7Hz,2H),3.82-3.66(m,1H),3.52-3.21(m,2H),1.64(q,J=7.2Hz,1H), 1.58(s,3H),1.56-1.38(m,6H),1.38-1.17(m,12H)0.87(t,J=6.6Hz,3H).

[0136] Example 3 Preparation of Compound I-35

[0137]

[0138] Step 1: At room temperature, itaconic anhydride 1-5 (2.24 g, 20 mmol) was added to n-octanol 1-7 (2.69 g, 20.7 mmol) and stirred at 100°C for 5 h. The sample was spin-dried and the crude spectrum was monitored. After the reaction of the raw materials was completed, 3.0 g of product 1-10 was purified by beating with n-hexane, with a yield of 62%. (The ratio of the product with double bonds on both sides is about 12:1)

[0139] Step 2: Dissolve 2.0 g of carboxylic acid compound 1-11 and 1.0 g of alcohol 1-10 in dichloromethane (40 mL), add 4-dimethylaminopyridine (503 mg, 4.1 mmol), N,N-diisopropylethylamine (3.2 g, 24.7 mmol), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.37 g, 12.4 mmol) at 0°C, react at room temperature for 8 h, concentrate the reaction solution by spin drying, and purify by column to obtain 1.52 g of product 1-12, with a yield of 52%.

[0140] Step 3: Dissolve 1.52 g of precursor compound 1-12 in dichloromethane (7 mL), add trifluoroacetic acid (7 mL), react at room temperature for 8 h, and concentrate the reaction solution to dryness to obtain 1.50 g of product, which is directly used in the next step (the ratio of the product with double bonds on both sides is about 12:1). 1 H NMR (400 MHz, CDCl 3 )δ6.48(s,1H),5.87(s,1H),4.79(s,2H),4.12(t,J=6.8Hz,2H),3.43(s,2H),1.62(t,J=7.0Hz,2H),1.35-1.24(m,10H),0.87(t,J=6.7Hz,3H).

[0141]

[0142] Step 4: Dissolve the precursor compound FI-2 (200 mg), carboxylic acid compound 1-13 (151 mg) and DBU (97 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system and extracted with ethyl acetate (3×10 mL). The organic phases were combined and precipitated with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column to obtain 40 mg of light yellow oily product I-35 with a yield of 14%. 1 H NMR (400 MHz, CDCl 3 )δ7.54(d,J=6.4Hz,2H),7.40(dq,J=22.0,7.4Hz,4H),7.17-7.04(m,2H),7.00 -6.86(m,1H),6.44(s,0.5H),6.38(s,0.5H),5.81(s,0.5H),5.76(s,0.5H),4.8 2-4.51(m,2H),4.08(q,J=7.3Hz,2H),3.75(dd,J=7.1,2.5Hz,1H),3.35(d,J=1 6.7Hz,2H),1.68-1.40(m,8H),1.39-1.16(m,10H),0.87(dt,J=7.1,3.4Hz,3H).

[0143] Example 4 Preparation of Compound I-48

[0144]

[0145] Step 1: Dissolve 300 mg of carboxylic acid compound 1-9 and 160 mg of alcohol 1-22 in dichloromethane (6 mL), add 4-dimethylaminopyridine (75 mg, 0.6 mmol), N,N-diisopropylethylamine (480 mg, 3.57 mmol), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (356 mg, 1.79 mmol) at 0°C, react at room temperature for 8 h, concentrate the reaction solution by spin drying, and purify by column to obtain 300 mg of product 1-23 with a yield of 70%.

[0146] Step 2: 395 mg of the precursor compound 1-23 was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.4 mL) was added, and the mixture was reacted at room temperature for 7 h. The reaction solution was concentrated under reduced pressure and purified by column to obtain 150 mg of the product 1-24 with a yield of 62%. 1 H NMR (400 MHz, CDCl 3)δ6.36(s,1H),5.87-5.74(m,1H),4.51(s,2H),4.15(t,J=6.7Hz,2H),3.4 4(s,2H),1.65(p,J=6.6Hz,2H),1.39-1.18(m,10H),0.87(t,J=6.7Hz,3H).

[0147]

[0148] Step 3: Dissolve the precursor compound FI-2 (265 mg, 0.67 mmol), carboxylic acid compound 1-21 (200 mg, 0.67 mmol) and DBU (129 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system and extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column to obtain 168 mg of light yellow oily product I-48 with a yield of 45%. 1 H NMR (400 MHz, CDCl 3 )δ7.54(d,J=7.2Hz,2H),7.41(dt,J=22.1,6.8Hz,4H),7.18-7.02(m,2H),6.99 -6.85(m,1H),6.37(s,0.5H),6.33(s,0.5H),5.78(s,0.5H),5.73(s,0.5H),4.7 4-4.44(m,2H),4.14(dt,J=9.2,6.7Hz,2H),3.74(dd,J=7.3,3.8Hz,1H),3.42( d,J=21.8Hz,2H),1.75-1.41(m,8H),1.40-1.16(m,10H),0.87(t,J=6.5Hz,3H).

[0149] Example 5 Preparation of Compound I-53

[0150]

[0151] At room temperature, FI-2 (1.40 g, 3.52 mmol), I-24 (854.00 mg, 3.52 mmol) and DBU (693.00 mg, 4.55 mmol) were dissolved in dry acetonitrile (30 mL) and stirred at room temperature for 12 h. After the reaction was completed as monitored by TLC, 10% sodium thiosulfate aqueous solution (20 mL) was added to the reaction system, extracted with ethyl acetate (3×10 mL), the organic phases were combined and dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by flash column chromatography (dichloromethane / petroleum ether (v / v) = 10-50%), monitored by TLC (dichloromethane / petroleum ether (v / v) = 1 / 1), and Rf = 0.2-0.3 was collected to obtain a light yellow oily compound I-53 (846.0 mg, yield 46.9%).

[0152] 1 H NMR (400 MHz, CDCl 3 )δ7.58-7.50(m,2H),7.47-7.33(m,4H),7.17-7.05(m,2H),6.98-6.91(m,1H),6.29(d,J=51.6Hz,1H),5.75(d,J=27.6Hz,1H),4.06(dt,J=1 8.3, 6.8Hz, 2H), 3.79-3.70 (m, 1H), 3.39-3.17 (m, 2H), 1.65-1.50 (m, 7H), 1.47 (d, J = 5.4Hz, 1H), 1.35-1.20 (m, 10H), 0.88 (t, J = 6.6Hz, 3H).

[0153] Example 6 Preparation of Compound I-53-1

[0154]

[0155] Step 1: Dissolve the precursor compound FI-2 (300 mg, 0.75 mmol), itaconate monomethyl ester 1-3 (72 mg, 0.75 mmol) and DBU (147 μL, 0.98 mmol) in anhydrous acetonitrile (3 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system, extracted with ethyl acetate (3×10 mL), and the organic phases were combined and washed with anhydrous Na 2 SO 4 Dry, filter, and concentrate under reduced pressure to obtain a crude product. The crude product is purified by column to obtain 140 mg of light yellow oily product I-53-1 with a yield of 47%. 1 H NMR (400 MHz, CDCl3 )δ7.53(d,J=8.3Hz,2H),7.50-7.31(m,4H),7.18-7.03(m,2H),7.02-6.87(m,1H),6.36(s,0.5H),6. 24(s,0.5H),5.79(s,0.5H),5.72(s,0.5H),3.82-3.58(m,4H),3.44-3.14(m,2H),1.58-1.46(m,6H).

[0156] Example 7 Preparation of Compound I-53-2

[0157]

[0158] Step 1: Dissolve the precursor compound FI-2 (200 mg, 0.5 mmol), monobutyl itaconate 1-4 (93 mg, 0.5 mmol) and DBU (98 μL, 0.65 mmol) in anhydrous acetonitrile (3 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 25%. A 10% aqueous sodium thiosulfate solution was added to the reaction system, extracted with ethyl acetate (3×10 mL), and the organic phases were combined and washed with anhydrous Na 2 SO 4 Dry, filter, and concentrate under reduced pressure to obtain a crude product. The crude product is purified by column to obtain 116 mg of light yellow oily product I-53-2 with a yield of 51%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(d,J=7.1Hz,2H),7.48-7.32(m,4H),7.18-7.05(m,2H),7.00-6.89(m,1H),6.36(s,0.5H),6.23(s,0.5H),5.78(s,0.5H),5.71(s ,0.5H),4.07(dt,J=17.9,6.7Hz,2H),3.81-3.67(m,1H),3.42-3.10(m,2H),1.68-1.44(m,8H),1.44-1.23(m,2H),0.91(q,J=7.6Hz,3H).

[0159] Example 8 Preparation of Compound I-53-3

[0160]

[0161] Step 1: At room temperature, itaconic anhydride 1-5 (1.12 g) was added to dodecanol 1-35 (2.0 g) and stirred at 80°C for 1 h. Samples were taken and spin-dried for crude spectrum monitoring. After the reaction of the raw materials was complete, 2.0 g of product 1-36 was obtained by slurrying and purification with n-hexane, with a yield of 77%. 1 H NMR (400 MHz, CDCl 3 )δ6.45(s,1H),5.82(s,1H),4.09(t,J=6.7Hz,2H),3.33(s,2H),1.62(p,J=6.8Hz,2H),1.40-1.18(m,18H),0.88(t,J=6.7Hz,3H).

[0162]

[0163] Step 2: Dissolve the precursor compound FI-2 (200 mg), carboxylic acid compound 1-36 (185 mg) and DBU (97 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 30%. A 10% sodium thiosulfate aqueous solution was added to the reaction system, extracted with ethyl acetate (3×10 mL), and the combined organic phases were precipitated with anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to obtain a crude product. The crude product is purified by column to obtain 117 mg of light yellow oily product I-53-43 with a yield of 42%. 1 HNMR (400MHz, CDCl 3 )δ7.58-7.50(m,2H),7.48-7.32(m,4H),7.17-7.03(m,2H),6.94(q,J=5.8Hz,1H),6.35(s,0.5H),6.23(s,0.5H),5.78(s,0.5H),5. 71(s,0.5H),4.14-3.96(m,2H),3.82-3.67(m,1H),3.41-3.15(m,2H),1.68-1.39(m,9H),1.38-1.16(m,17H),0.88(t,J=6.6Hz,3H).

[0164] Example 9 Preparation of Compound I-55

[0165]

[0166] Step 1: Dissolve itaconic anhydride 1-5 (2 g, 17.8 mmol) and p-methoxybenzyl alcohol 1-6 (2.5 g, 17.8 mmol) in n-hexane (10 mL) and toluene (10 mL) at room temperature and stir at room temperature for 16 h. Take a sample and spin dry it, and monitor the crude spectrum. After the reaction of the raw materials is complete, spin dry the reaction liquid, and purify it with n-hexane to obtain 3.0 g of product A1, with a yield of 67% (the ratio of the product with double bonds on both sides is about 10:1). 1 H NMR (400 MHz, CDCl 3 )δ7.28(d,J=8.4Hz,2H),6.88(d,J=8.5Hz,2H),6.46(s,1H),5.82(s,1H),5.09(s,2H),3.80(d,J=1.4Hz,3H),3.36(s,2H).

[0167] Step 2: 3 g of carboxylic acid compound A1 and 1.66 g of octanol 1-7 were dissolved in dichloromethane (50 mL), 4-dimethylaminopyridine (776 mg, 6.35 mmol) and N,N-diisopropylethylamine (6.6 mL, 38.1 mmol) were added, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.65 g, 19 mmol) was added at 0°C, and the mixture was reacted at room temperature for 8 h. The reaction solution was concentrated by spin drying and purified by column to obtain 1.0 g of product 1-8 with a yield of 22%. (The ratio of the product with double bonds on both sides is about 8:1).

[0168] Step 3: Dissolve 1.0 g of the precursor compound 1-8 in dichloromethane (30 mL), add trifluoroacetic acid (0.64 mL), react at room temperature for 8 h, spin dry and concentrate the reaction solution, and purify it by column to obtain 200 mg of product 1-9 with a yield of 29%. (The ratio of the product with double bonds on both sides is about 10:1). 1 H NMR (400 MHz, CDCl 3 )δ6.34(s,1H),5.73(s,1H),4.16(t,J=6.8Hz,2H),3.38(s,2H),1.66(t,J=7.0Hz,2H),1.40-1.21(m,10H),0.88(t,J=6.6Hz,3H).

[0169]

[0170] Step 4: Dissolve the precursor compound FI-2 (164 mg, 0.41 mmol), carboxylic acid compound 1-9 (100 mg, 0.41 mmol) and DBU (80 μL, 0.53 mmol) in anhydrous acetonitrile (3 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 30%. A 10% aqueous sodium thiosulfate solution was added to the reaction system, extracted with ethyl acetate (3×10 mL), and the organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column to obtain 101 mg of light yellow oily product I-55 with a yield of 48%. 1 H NMR (400 MHz, CDCl 3 )δ7.54(d,J=7.7Hz,2H),7.40(dq,J=20.7,7.5Hz,4H),7.19-7.14(m,2H),6.95-6.82(m,1H),6.34(s,0.5H),6.28(s,0.5H),5.72(s,0. 5H),5.62(s,0.5H),4.13(dt,J=17.9,6.8Hz,2H),3.75(t,J=7.3Hz,1H),3.42-3.18(m,2H),1.75-1.15(m,18H),0.88(t,J=6.6Hz,3H).

[0171] Example 9 Preparation of Compound I-55-1

[0172]

[0173] Step 1: Dissolve 1.5g of carboxylic acid compound A1 and 470g of n-butanol 1-38 in dichloromethane (50mL), add 4-dimethylaminopyridine (388mg), N,N-diisopropylethylamine (1.8g), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.83g) at 0°C, react at room temperature for 8h, spin dry and concentrate the reaction solution, and purify by column to obtain 1.2g of product 1-39, with a yield of 59%. (The ratio of the product with double bonds on both sides is about 8:1).

[0174] Step 2: Dissolve 1.45 g of precursor compound 1-39 in dichloromethane (30 mL), add trifluoroacetic acid (0.64 mL), react at room temperature for 8 h, spin dry and concentrate the reaction solution, and purify it by column to obtain 600 mg of product 1-40 with a yield of 60%. (The ratio of the product with double bonds on both sides is about 15:1). 1 H NMR (400 MHz, CDCl 3)δ6.43-6.30(m,1H),5.80-5.69(m,1H),4.18(t,J=6.6Hz,2H),3.39(d,J= 1.2Hz,2H),1.71-1.55(m,2H),1.51-1.27(m,2H),,0.94(t,J=7.3Hz,3H).

[0175]

[0176] Step 3: Dissolve the precursor compound FI-2 (180 mg, 0.46 mmol), carboxylic acid compound 1-40 (85 mg, 0.46 mmol) and DBU (87 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system and extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 Dry, filter, and concentrate under reduced pressure to obtain a crude product. The crude product is purified by column to obtain 110 mg of light yellow oily product I-55-1 with a yield of 57%. 1 H NMR (400 MHz, CDCl 3 )δ7.59-7.49(m,2H),7.50-7.31(m,4H),7.17-7.04(m,2H),6.93-6.83(m,1H),6.34(s,0.5H),6.28(s,0.5H),5.71(s,0.5H),5.61 (s,0.5H),4.14(dt,J=17.3,6.6Hz,2H),3.74(dd,J=7.2,2.6Hz,1H),3.42-3.17(m,2H),1.71-1.31(m,10H),0.87(t,J=6.7Hz,3H).

[0177] Example 10 Preparation of Compound I-55-2

[0178]

[0179] Step 1: 3.5 g of carboxylic acid compound A1 and 2.76 g of dodecanol 1-35 were dissolved in dichloromethane (50 mL), 4-dimethylaminopyridine (904 mg) and N,N-diisopropylethylamine (4.2 g) were added, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.26 g) was added at 0°C, and the mixture was reacted at room temperature for 8 h. The reaction solution was concentrated by spin drying and purified by column to obtain 2.78 g of product 1-36 with a yield of 45%. (The ratio of the product with double bonds on both sides is about 8:1).

[0180] Step 2: Dissolve 1.0 g of the precursor compound 1-36 in dichloromethane (30 mL), add trifluoroacetic acid (0.64 mL), react at room temperature for 8 h, concentrate the reaction solution by spin drying, and purify by column to obtain 650 mg of the product 1-37 with a yield of 65%. 1 H NMR (400 MHz, CDCl 3 )δ6.36(s,1H),5.74(s,1H),4.17(t,J=6.8Hz,2H),3.39(s,2H),1.78-1.55(m,2H),1.26(d,J=7.6Hz,18H),0.86(t,J=6.7Hz,3H).

[0181]

[0182] Step 3: Dissolve the precursor compound FI-2 (200 mg, 0.51 mmol), carboxylic acid compound 1-37 (160 mg, 0.51 mmol) and DBU (97 μL) in dry acetonitrile (5 mL) at room temperature and stir at room temperature for 12 h. TLC monitoring showed that the precursor compound remained about 20%. A 10% aqueous sodium thiosulfate solution was added to the reaction system and extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with anhydrous Na 2 SO 4 Dry, filter, and concentrate under reduced pressure to obtain a crude product. The crude product is purified by column to obtain 128 mg of light yellow oily product I-55-2 with a yield of 47%. 1 H NMR (400 MHz, CDCl 3 )δ7.57-7.50(m,2H),7.47-7.33(m,4H),7.16-7.05(m,2H),6.93-6.8 3(m,1H),6.34(s,0.5H),6.28(s,0.5H),5.71(s,0.5H),5.61(s,0.5H) ,4.20-4.04(m,2H),3.79-3.67(m,1H),3.36-3.20(m,2H),1.71-1.58 (m,2H),1.57-1.39(m,7H),1.38-1.18(m,19H),0.88(t,J=6.8Hz,3H).

[0183] Example 11 Preparation of Compound I-58

[0184]

[0185] Step 1: Dissolve the raw alcohol (2.32 g) in dichloromethane (60 mL), add imidazole (3.27 g), add tert-butyldimethylsilyl chloride (6.0 g) at 0 ° C, react at room temperature for 3 h, add water and extract with dichloromethane (3×20 mL), combine the organic phases and use anhydrous Na 2 SO 4 After drying, suction filtration, concentration under reduced pressure and column purification, 3.82 g of product 1-31 was obtained with a yield of 83%.

[0186] Step 2: The precursor compound (3 g) was dissolved in tetrahydrofuran (7 mL) and water (7 mL), lithium hydroxide (620 mg) was added, and the reaction was carried out at 50 ° C for 8 h. After the reaction was completed, the pH was adjusted to 2 with 1 M hydrochloric acid, extracted with ethyl acetate, and the organic phases were combined and precipitated with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to obtain 2.0 g of crude product 1-32 with a yield of 70%.

[0187] Step 3: Dissolve 2.0 g of carboxylic acid compound 1-32 and 1.18 g of alcohol 1-7 in dichloromethane (8 mL), add 4-dimethylaminopyridine (553 mg) and N,N-diisopropylethylamine (2.58 g), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.6 g) at 0°C, react at room temperature for 6 h, add water and extract with dichloromethane (3×20 mL), combine the organic phases and precipitate with anhydrous Na 2 SO 4 After drying, suction filtration, concentration under reduced pressure and column purification, 1.2 g of product 1-33 was obtained with a yield of 40%.

[0188] Step 4: Dissolve 1.2 g of the precursor compound 1-33 in tetrahydrofuran (36 mL), add 1 M tetrabutylammonium fluoride solution in tetrahydrofuran (3.6 mL) at 0°C and react for 1 h. After the reaction, add water. Extract with ethyl acetate (3×20 mL), combine the organic phases and add anhydrous Na 2 SO 4 After drying, suction filtration, concentration under reduced pressure and column purification, 500 mg of product 1-34 was obtained with a yield of 65%. 1 H NMR (400 MHz, CDCl 3 )δ6.25(s,1H),5.82(s,1H),4.33(d,J=6.3Hz,2H),4.17(t,J=6.7Hz,2H),1.74-1.56(m,2H),1.44-1.17(m,10H),0.88(t,J=6.7Hz,3H).

[0189]

[0190] Step 5: Dissolve 222 mg of carboxylic acid compound 1-1 and 200 mg of alcohol 1-34 in dichloromethane (3 mL), add 4-dimethylaminopyridine (56 mg), N,N-diisopropylethylamine (337 μL), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (143 mg) at 0°C, react at room temperature for 5 h, concentrate the reaction solution by spin drying, and purify by column to obtain 217 mg of product I-58 with a yield of 56%. 1 H NMR (400 MHz, CDCl 3 )δ7.59-7.50(m,2H),7.48-7.32(m,4H),7.20-7.08(m,2H),6.30(s,1H),5.67(s,1H),4.93-4.75(m,2H) ,4.17-4.08(m,2H),3.80(q,J=7.1Hz,1H),1.70-1.51(m,3H),1.36-1.19(m,12H),0.87(t,J=6.7Hz,3H).

[0191] Example 12 Preparation of Compound I-58-1

[0192]

[0193] Step 1: 183 mg of carboxylic acid compound 1-1 and 120 mg of alcohol 1-41 were dissolved in dichloromethane (5 mL), 4-dimethylaminopyridine (45 mg) and N,N-diisopropylethylamine (213 mg) were added, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (215 mg) was added at 0°C. The reaction was allowed to react at room temperature for 8 h. According to TLC monitoring, the precursor compound remained at about 40%. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and precipitated with anhydrous Na 2 SO 4 After drying and concentration under reduced pressure, the crude product was obtained. The crude product was purified by column to obtain 35 mg of light yellow oily product I-58-1 with a yield of 12%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(d,J=8.0Hz,2H),7.40(ddd,J=14.6,13.3,7.3Hz,4H),7.14(t,J=10.0Hz,2H),6.30(s,1H),5.68(s,1H),4 .84(s,2H),4.15(t,J=6.1Hz,2H),3.80(q,J=7.1Hz,1H),1.68-1.52(m,6H),1.42-1.31(m,3H),1.00-0.89(m,3H).

[0194] Example 12 Preparation of Compound I-58-2

[0195]

[0196] Step 1: Dissolve 512 mg of carboxylic acid compound 1-1 and 567 mg of alcohol 1-42 in dichloromethane (10 mL), add 4-dimethylaminopyridine (128 mg), N,N-diisopropylethylamine (597 mg), add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (600 mg) at 0°C, react at room temperature for 8 h, and monitor by TLC. The remaining amount of the precursor compound is about 40%. Water is added to quench the reaction, and the mixture is extracted with ethyl acetate (3×10 mL). The organic phases are combined and washed with anhydrous Na 2 SO 4 After drying and concentrating under reduced pressure, the crude product was obtained. The crude product was purified by column to obtain 160 mg of light yellow oily product I-58-2 with a yield of 15%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(d,J=7.8Hz,2H),7.39(ddd,J=14.6,13.4,7.3Hz,4H),7.14(t,J=10.0Hz,2H),6.30(s,1H),5.67(s,1H),4.84( s,2H),4.13(t,J=6.0Hz,2H),3.80(q,J=7.2Hz,1H),1.69-1.51(m,7H),1.27(d,J=17.0Hz,16H),0.88(t,J=6.7Hz,3H).

[0197] The technical solution of the present invention is further illustrated by experiments below.

[0198] Experimental Example 1 Self-assembly of compounds

[0199] 1. Experimental Methods

[0200] The appearance and solubility of compound I-53 were observed.

[0201] 1 mL of distilled water was added to a vial containing 1 mmol of compound I-53, and the mixture was shaken at room temperature to obtain a milky white solution. The particle size of each compound was measured using a Brookhaven particle size potentiometer.

[0202] 2. Experimental Results

[0203] As shown in Table 1, the compounds of the present invention form nano-sized particles by self-assembly.

[0204] Table 1 Particle size values ​​of the compounds of the present invention

[0205]

[0206]

[0207] Experimental Example 2 Sustained release of compounds in mouse plasma in vitro

[0208] 1. Experimental Methods

[0209] Experimental animals: 8-10 week old C57BL / 6J male mice were selected for the experiment. The mice were housed in sawdust litter cages at 25±1 degrees Celsius, 40% to 60% humidity, 12h light / 12h dark, with no more than 5 mice per cage, and free access to water and food.

[0210] 1. Expose the rats to 5% isoflurane for 2-3 minutes. After the rats are fully anesthetized, fix them on a mouse board and continue to use 2% isoflurane to maintain anesthesia. Take about 1 mL of arterial blood from each rat, anticoagulate with heparin, centrifuge at 3500 rpm for 10 minutes, and take the supernatant for later use.

[0211] 2. Take three 1 mL plasma samples from each group and place them in a 37°C water bath for about 15 to 30 minutes. Add 100 μL of 50 mg / mL compound I-53 and control drug Flurbiprofen axetil (Fa) to each group, so that the plasma concentration is 100 ug / mL.

[0212] 3. In the Fa group, 50 μL of sample was taken at 0, 20, 30, 40, 60 and 120 s, and 150 μL of acetonitrile was added to precipitate the protein. The supernatant was collected after centrifugation at 20,000 rpm for 10 min, and the original drug and its metabolite Flurbiprofen (Flurbiprofen, F) were measured by high performance liquid chromatography (HPLC).

[0213] In the I-53 group, 50 μL of sample was taken at 0, 5, 10, 20, 40, 60 and 120 min, 150 μL of acetonitrile was added to precipitate the protein, and the supernatant was taken after centrifugation at 20,000 rpm for 10 min and measured by HPLC.

[0214] 2. Experimental Results

[0215] like Figure 1 As shown in the figure, Fa can be completely metabolized to release F within 2 minutes, while I-53 needs at least 2 hours to metabolize and release most of F. The results show that I-53 achieves sustained release.

[0216] Experimental Example 3 Analgesic efficacy of the compound on chronic inflammatory pain model

[0217] 1. Experimental Methods

[0218] Experimental animals: 8-10 week old C57BL / 6J male mice were selected for the experiment. The mice were housed in sawdust litter cages at 25±1 degrees Celsius, 40% to 60% humidity, 12h light / 12h dark, with no more than 5 mice per cage, and free access to water and food.

[0219] Experimental protocol:

[0220] 1. 20 μL of Freund's complete adjuvant (CFA) was injected subcutaneously into the left sole of the mouse to establish a chronic inflammatory pain model (CFA model);

[0221] 2. Behavioral experiments:

[0222] The von Frey test was used to evaluate the analgesic effect of the compound of the present invention (administered at an equal molar mass with Fa), the control drug Fa and the 4-OI mixed drug in the CFA model. The mice were placed in a pain behavior plastic compartment with air holes (20×20×14 cm) and a metal wire mesh (0.5×0.5 cm) at the bottom. Adaptation began 3 days before the test. On the day of the test, the mechanical paw withdrawal threshold was assessed using an electronic von Frey. The tip of the stimulus was vertical to the palm of the left hind paw of the mouse, and pressure was applied gradually. Rapid paw withdrawal or retreat was a positive reaction, and the pressure value that caused the reaction was recorded at this time. Repeat the measurement three times and take the average value.

[0223] 2. Experimental Results

[0224] like Figure 2 As shown, in the CFA model, the compounds of the present invention and the mixed drug group of Fa and 4-OI can relieve inflammatory pain. In addition, the compounds of the present invention have better and longer efficacy than the mixed drug group, among which compounds I-53, I-58, I-55-1, I-55-2, I-53-3, etc. all have good effects.

[0225] It can be seen from the above embodiments and experimental examples that the compounds of the present invention can self-assemble and achieve the sustained release effect of flurbiprofen and 4-octylitaconic acid (or analogs thereof), thereby achieving the effect of enhancing the anti-inflammatory and analgesic efficacy and reducing the adverse reactions of the two, and has a good application prospect.

Claims

1. A compound of formula I, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The structural formula of the compound shown in Formula I is as follows: in, X1 is selected from oxygen, carbonyl, substituted or unsubstituted methylene; wherein the substituent is selected from methyl; X2 is selected from oxygen or carbonyl; X3 is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH2; X4 is selected from substituted or unsubstituted methylene; wherein the substituent is selected from methyl or =CH2; X5 is selected from oxygen, carbonyl, substituted or unsubstituted methylene; wherein the substituent is selected from =CH2; X6 is selected from oxygen or carbonyl; X7 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from methyl or =CH2; X8 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH2; X9 is absent, or is selected from carbonyl; X 10 is absent, or is selected from oxygen, substituted or unsubstituted methylene; wherein the substituent is selected from =CH2; X 11 is absent, or is selected from substituted or unsubstituted methylene; wherein the substituent is selected from =CH2; X 12 is absent, or is selected from carbonyl; X 13 is absent, or is selected from oxygen; R is selected from H or C1~C 12 alkyl.

2. The compound according to claim 1, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The structural formula of the compound is shown in Formula II: in, R1 is selected from methyl or H, R2 is connected to the rest of the molecule by a single bond or a double bond; when R2 is connected to the rest of the molecule by a single bond, R2 is selected from H; when R 10 When connected to the rest of the molecule by a double bond, R2 is selected from =CH2; R3 is connected to the rest of the molecule by a single bond or a double bond; when R3 is connected to the rest of the molecule by a single bond, R3 is selected from H; when R 11 When connected to the rest of the molecule by a double bond, R3 is selected from =CH2; R is selected from H or C1~C 12 alkyl.

3. The compound according to claim 2, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The compound structural formula is as follows:

4. The compound according to claim 1, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The structural formula of the compound is shown in Formula III: in, R4 is selected from H or methyl, R5 is connected to the rest of the molecule by a single bond or a double bond; when R5 is connected to the rest of the molecule by a single bond, R5 is selected from H; when R5 is connected to the rest of the molecule by a double bond, R5 is selected from =CH2; R6 is connected to the rest of the molecule by a single bond or a double bond; when R6 is connected to the rest of the molecule by a single bond, R6 is selected from H; when R6 is connected to the rest of the molecule by a double bond, R6 is selected from =CH2; R is selected from C1~C 12 alkyl.

5. The compound according to claim 4, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The compound structural formula is as follows:

6. The compound according to claim 1, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The structural formula of the compound is shown in Formula IV: in, R7 is connected to the rest of the molecule by a single bond or a double bond; when R7 is connected to the rest of the molecule by a single bond, R7 is selected from H; when R7 is connected to the rest of the molecule by a double bond, R7 is selected from =CH2; R8 is connected to the rest of the molecule by a single bond or a double bond; when R8 is connected to the rest of the molecule by a single bond, R8 is selected from H; when R8 is connected to the rest of the molecule by a double bond, R8 is selected from =CH2; R is selected from C1~C 12 alkyl.

7. The compound according to claim 6, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The compound structural formula is as follows:

8. A method for preparing the compound according to claim 2 or 3, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The steps include: Step 1, reacting flurbiprofen with a chlorination reagent to obtain compound I-53-1; Step 2, reacting compound I-53-1, paraldehyde and an iodination reagent to obtain compound I-53-2; Step 3, reacting compound I-53-2 and compound F to obtain the compound represented by formula II.

9. The preparation method according to claim 8, characterized in that: In step 1, the chlorination agent is selected from at least one of oxalyl chloride, thionyl chloride, phosphorus trichloride, phosphorus pentachloride or triphosgene; and / or, the reaction is performed with or without a solvent; when a solvent is used in the reaction, the solvent is selected from at least one of dichloromethane, petroleum ether, n-hexane, tetrahydrofuran, toluene or benzene; and / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of N,N-dimethylformamide, N,N-dimethylaniline and pyridine, triethylamine or N-methylpyrrolidone; And / or, the reaction temperature ranges from -20°C to 80°C.

10. The preparation method according to claim 8, characterized in that: In step 2, the iodination reagent is selected from at least one of sodium iodide or elemental iodine; and / or, the reaction solvent is selected from at least one of dichloromethane and acetonitrile; And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of AlCl3 and zinc chloride; And / or, the reaction temperature ranges from 0°C to 40°C.

11. The preparation method according to claim 8, characterized in that: In step 3, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane or N,N-dimethylformamide; And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of DBU, sodium carbonate, potassium carbonate, cesium carbonate or triethylamine; And / or, the reaction temperature ranges from 0°C to 40°C.

12. A method for preparing the compound according to claim 4 or 5, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, characterized in that: The steps include: Step a, reacting flurbiprofen with compound C to obtain compound D; Step b, reacting compound D with compound E to obtain a compound represented by formula III.

13. The preparation method according to claim 12, characterized in that: In step 4, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane or N,N-dimethylformamide; And / or, the reaction is carried out under the action of a base, wherein the base is selected from tetrabutylammonium hydrogen sulfate, sodium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate or triethylamine And / or, the reaction temperature is in the range of 0°C to 40°C.

14. The preparation method according to claim 12, characterized in that: In step 5, the reaction solvent is selected from at least one of acetonitrile, ethyl acetate, dichloromethane, chloroform, acetone, tetrahydrofuran, toluene, 1,4-dioxane, diethyl ether, n-hexane, cyclohexane, N,N-dimethylformamide, N,N-dimethylacetamide or DMSO; and / or, the reaction is carried out under the action of a base, wherein the base is selected from at least one of DBU, sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, potassium bicarbonate or sodium bicarbonate; And / or, the reaction is carried out under the action of a catalyst, wherein the catalyst is selected from at least one of sodium iodide and potassium iodide; And / or, the reaction temperature ranges from 0°C to 80°C.

15. A self-assembled structure formed by self-assembly of the compound according to any one of claims 1 to 7, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof.

16. Use of the compound according to any one of claims 1 to 7, or a salt thereof, or a crystal form thereof, or a stereoisomer thereof, or the self-assembled structure according to claim 23 in the preparation of an anti-inflammatory and / or analgesic drug.

17. A drug for anti-inflammatory and / or analgesic purposes, characterized in that: It is prepared by using the compound described in any one of claims 1 to 7, or its salt, or its crystal form, or its stereoisomer, or the self-assembled structure described in claim 15 as an active ingredient, and adding pharmaceutically acceptable excipients or auxiliary ingredients.

Citation Information

Patent Citations

  • Aryl propionic acid derivative composition and pharmaceutical purpose

    CN106661061A

  • Ketorolac derivative, pharmaceutical composition as well as preparation method and application of ketorolac derivative

    CN113831342A

  • Compound for preventing and treating pain and inflammation and application thereof

    CN114504579A

  • Antibiotic conjugates with nonsteroidal Anti-inflammatory drugs

    US20140256666A1

  • Derivatives of itaconic acid and their use as Anti-inflammatory agents

    WO2023017269A1